Drugs / KOCITAF
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05924438 | Nov 2023 → Jun 2026 overdue | HIV infectious disease | Professor Francois Venter | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KOCITAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05924438 ↗ |
| Route | Oral | “Treatment Group 2 Participants will receive dolutegravir, as part of a fixed-dose oral combination with tenofovir alafenamide plus emtricitabine (DTG/TAF/FTC, KOCITAF) tablets...” NCT05924438 ↗ |